| [1] |
戴色莺, 沈张伟, 范引光, 等. 我国艾滋病预防控制中流行病学研究进展[J]. 中华疾病控制杂志,2015,19(12):1282-1285.
|
| [2] |
佚名. 2016年5月全国艾滋病性病疫情及主要防治工作进展[J]. 中国艾滋病性病,2016(7):487.
|
| [3] |
王辉, 周伯平. AIDS抗病毒药物的不良反应[J]. 传染病信息,2014(6):369-372.
|
| [4] |
Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review[J]. AIDS,2006,20(17):2165-2174.
|
| [5] |
Hoy J, Young B. Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?[J]. Curr Opin HIV AIDS,2016,11(3):301.
|
| [6] |
Mccomsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers[J]. Clini Infect Dis,2010,51(8):937-946.
|
| [7] |
Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system[J]. J Clin Endocrinol Metab,2008,93(9):3499-3504.
|
| [8] |
Shiau S, Broun EC, Arpadi SM, et al. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis[J]. AIDS,2013,27(12):1949-1957.
|
| [9] |
Torti C, Mazziotti G, Soldini PA, et al. High prevalence of radiological vertebral fractures in HIV-infected males[J]. Endocrine,2012,41(3):512-517.
|
| [10] |
王萍萍, 柯耀华, 张浩, 等. 绝经后妇女740例脆性骨折部位与骨密度关系的分析[J]. 中国科医学,2010,13(4):372-373.
|
| [11] |
陈瑾瑜, 游利, 潘凌, 等. 老年患者脆性骨折1072例分析[J]. 世界临床药物,2016(6):385-389.
|
| [12] |
Haskelberg H, Carr A, Emery S. Bone turnover markers in HIV disease[J]. AIDS Rev,2011,13(4):240-250.
|
| [13] |
Natsag J, Kendall M, Sellmeyer D, et al. Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappa B ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density[J]. HIV Med,2016,17(3):196-205.
|
| [14] |
张久聪, 郑晓凤, 汪泳, 等. 获得性免疫缺陷综合征抗病毒治疗药物研究进展[J]. 生物技术通讯,2016,27(5):732-737.
|
| [15] |
Mary-Krause M, Viard J, Ename-Mkoumazok B, et al. Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy[J]. J Clin Densitom,2012,15(4): 422-433.
|
| [16] |
Grant PM, Kitch D, Mccomsey GA, et al. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults[J]. HIV Clin Trials,2015,16(2):66-71.
|
| [17] |
Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study[J]. J Infect Dis,2009,200(11): 1746-1754.
|
| [18] |
Lima ALLM, Godoy AL, Gobbi RG, et al. Orthopedic complictions in HIV patients [J]. Rev Bras Ortop,2009,44(3):186-190.
|
| [19] |
Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans[J]. PLoS One,2011,6(2):e17217.
|
| [20] |
Bedimo R, Maalouf N M, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents[J]. AIDS,2012,26(7):825-831.
|
| [21] |
Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials[J]. Lancet,2015,385(9987):2606-2615.
|
| [22] |
Moran CA, Weitzmann MN, Ofotokun I. Bone Loss in HIV Infection[J]. Curr Treat Options Infect Dis,2017,9(1):52-67.
|
| [23] |
Grant PM, Kitch D, Mccomsey GA, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation[J]. Cli Infect Dis,2013,57(10):1483-1488.
|
| [24] |
Hansen AE, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection[J]. AIDS,2012,26(3):285-293.
|
| [25] |
Bregigeon S, Galinier A, Zaegelfaucher O, et al. Frailty in HIV infected people: a new risk factor for bone mineral density loss[J]. Aids,2017,31(11):1573-1577.
|
| [26] |
Shahar E, Segal E, Rozen GS, et al. Vitamin D status in young HIV infected women of various ethnic origins: Incidence of vitamin D deficiency and possible impact on bone density[J]. Clin Nutr,2013,32(1):83-87.
|
| [27] |
Albright P, Du P, Haas RE, et al. Evidence-based screening for low bone mineral density in HIV-infected men[J]. J Assoc Nurses AIDS Care,2014,25(6):532-540.
|
| [28] |
Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006[J]. Clin Infect Dis,2011,52(8):1061-1068.
|
| [29] |
Mayer KH, Amorosa V, Tebas P. Bone disease and HIV infection[J]. Clin Infect Dis,2006,43(1):111-112.
|
| [30] |
Pinzone MR, Moreno S, Cacopardo B, et al. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis[J]. AIDS Rev,2014,16(4):213-222.
|
| [31] |
Cummings SR, San MJ, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J]. N Engl J Med,2009,361(8):756-765.
|
| [32] |
Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the multiple outcomes of raloxifene evaluation (MORE) study[J]. J Bone Miner Res,2004,19(5):764-772.
|